Llwytho...
B-cell–targeted therapies in relapsing forms of MS
In recent years, there has been a significant increase in the therapeutic options available for the management of relapsing forms of MS. Therapies primarily targeting B cells, including therapeutic anti-CD20 monoclonal antibodies, have been evaluated in phase I, phase II, and phase III clinical tria...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Lippincott Williams & Wilkins
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5656409/ https://ncbi.nlm.nih.gov/pubmed/29082296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000405 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|